Amneal Pharmaceuticals Inc (Amneal) is a pharmaceutical company that specializes in the development, marketing, and distribution of a diverse range of essential medicines. This includes injectables, biosimilars, complex generics, and specialty branded pharmaceuticals. The company’s primary operations are conducted in India, the United States, and Ireland. It sells its products to wholesalers, chain pharmacies, distributors, hospitals, and individual pharmacies, both directly and indirectly.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Amneal’s focuses on developing new products, discovering, testing and improving existing products. It has had 105 products Generics with a pending ANDA and 94 products in various stages of development. The R&D pipeline has prioritized new product innovations in injectables, such as drug/device combinations, long-acting injectables, peptides, and large volume parenteral bags. Generics pipeline includes products across a broad range of therapeutic areas including central nervous system/pain, oncology, inflammation, cardiovascular, anti-infective, diabetes, rhinology, urology, dermatology, endocrinology, and hematology, among others. The speciality portfolio focuses on core therapeutic categories including endocrinology (Hypothyroidism), central nervous system disorders (Parkinson’s Disease, Spasticity, Migraine), and other therapeutic areas. The company has R&D centers in India, the U.S., and Ireland, with broad dosage capabilities. In FY2022, the company spent US$195.7 million on R&D, representing a decline as compared to previous year of 3.1% in FY2021, which as a percentage of revenue, stood at 8.8%.